ClinicalTrials.gg
Active, not recruitingNCT06188520CYCAD-1Updated Oct 28, 2026

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of AZD8421 and Camizestrant in ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), sponsored by AstraZeneca. Active, not recruiting at 13 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

How we know · 13 judgments

Updated Oct 28, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Enrollment
93rd of 125
55 · median 148
Started
2023
with 12 others
Phase 1/2
12 of 198
2 open now
Primary completion
2027-06
later than 27 of 49 live
Registered
174th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 93rd largest by enrollment of the 125 interventional ones that give a count, is one of 13 that started in 2023, is one of 12 in phase 1/2, reaches primary completion later than 27 of the 49 other live ones, and was the 174th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Read the detailed description

This is a first in-human study of AZD8421 administered to participants with advanced or metastatic solid tumors. The study will evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of AZD8421 alone and in combination with selected targeted anti-cancer drugs.

AZD8421 monotherapy (M1) will evaluate the safety, tolerability and pharmacokinetics of AZD8421 as monotherapy to identify a recommended Phase II dose (RP2D) in participants with ER+ HER2- advanced breast cancer previously treated with a CDK4/6i (Parts A and B) and participants with metastatic high-grade serous ovarian cancer previously treated with a platinum-based chemotherapy in the metastatic setting (Part B).

AZD8421 combination therapy (M2) will evaluate the safety, tolerability, and pharmacokinetics of different formulations of AZD8421 in combination with a CDK4/6 inhibitor (one or more of abemaciclib, ribociclib and palbociclib) and camizestrant (next generation oral SERD; referred to throughout as 'camizestrant') in participants with ER+ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor.

03

Conditions studied

  • ER+ HER2- Advanced Breast Cancer
  • High-grade Serous Ovarian Cancer (HGSOC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants only, aged 18 or above
  • Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best option for their next treatment based on response to and/or tolerability of prior therapy.
  • or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP.
  • performance status 0 to 1, and a minimum of 12 weeks.
  • At least one lesion that is measurable and/or non-measurable, as per v1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment.

Exclusion criteria

Exclusion Criteria:

  • Intervention with any of the following:
  • Any cytotoxic chemotherapy, agents, or other anti-cancer drugs for the treatment of advanced cancer from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is shorter) of the first dose of IMP (21 days for myelosuppressive therapies) other than GnRHa (eg, goserelin) and bone-stabilizing agents (eg, zoledronic acid, denosumab).
  • Any prescription or non-prescription drugs or other products, including herbal products, known to be moderate or strong inhibitors/inducers of /5 which cannot be discontinued prior to first dose of IMP and withheld throughout the study until 2 weeks after the last dose of study drug.
  • Drugs that have a known risk of Torsades de Pointes.
  • Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP.
  • Major surgical procedure or significant traumatic injury, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anesthesia during the study.
  • Any unresolved toxicities of Grade ≥ 2 from prior anti-cancer therapy (with the exception of alopecia). Participants with stable ≤ Grade 2 neuropathy are eligible.
  • Presence of life-threatening visceral disease, as judged by the Investigator, uncontrolled CNS metastatic disease. Participants with spinal cord compression and/or may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off for at least 4 weeks prior to start of IMP.
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or eg, infection requiring IV antibiotic therapy, or active infection including , , and (active viral infection is defined as requiring antiviral therapy; screening for chronic conditions is not required).
  • Any of the following cardiac criteria:
  • Mean resting > 470 msec obtained from a triplicate
  • Any abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Participants with controlled atrial fibrillation can be enrolled.
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death at \< 40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease.
  • \< 50%, and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure Grade ≥ 2, cerebrovascular accident, or .
  • Uncontrolled hypertension.
  • Inadequate bone marrow reserve or organ function as demonstrated by relevant laboratory values:
  • nausea and vomiting, uncontrolled chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of IMP(s).
  • History of to active or inactive of AZD8421 or drugs with a similar chemical structure or class to AZD8421.
  • Previous treatment with AZD8421 or with any CDK2-selective inhibitor, or protein kinase membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 1 (PKMYT1) inhibitor, or WEE1 inhibitor.
  • Currently pregnant (confirmed with positive pregnancy test), breast feeding, or planning to become pregnant. Participants of must agree to use one highly effective measure.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Module 1

    AZD8421 monotherapy

    Drug: AZD8421

  • Experimental
    Module 2A

    AZD8421 with camizestrant and CDK4/6 inhibitor

    Drug: AZD8421 · Drug: Camizestrant · Drug: Ribociclib · Drug: Palbociclib · Drug: Abemaciclib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs) as defined in the protocol.

    Percentage of participants with incidence of DLTs.

    Time frame: From start of treatment until the end of DLT period, assessed up to 28 days.

  2. Incidence of AEs/SAEs

    Percentage of participants with incidence of AEs/SAEs.

    Time frame: From start of treatment until the end of safety follow-up, approximately 18 months.

  3. Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.

    Percentage of participants with clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.

    Time frame: From start of treatment until the end of safety follow-up, approximately 18 months.

  4. Discontinuation of AZD8421 due to toxicity

    Percentage of participants that have discontinued AZD8421 due to toxicity.

    Time frame: From start of treatment until the end of safety follow-up, approximately 18 months.

Secondary outcomes

  1. Overall Response Rate (ORR)

    The percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR), according to RECIST v1.1, that occur prior to disease progression and/or initiation of subsequent anti-cancer therapy.

    Time frame: 8 weeks from start of treatment until end of treatment or objective disease progression, approximately 18 months.

  2. Duration of Response (DoR)

    The time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression).

    Time frame: 8 weeks from start of treatment until end of treatment or objective disease progression, approximately 18 months.

  3. Disease control rate (DCR)

    The percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 23 weeks after start of treatment.

    Time frame: 24 weeks after the start of treatment.

  4. Percentage change in tumor size

    The largest decrease (or smallest increase) in tumor size from baseline for a participant, using RECIST v1.1 assessments

    Time frame: From start of treatment through to EOT, progressive disease, death (in the absence of progression), start of subsequent anti-cancer therapy, whichever occurs first, approximately 18 months.

  5. Progression Free Survival (PFS)

    Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression.

    Time frame: From start of treatment through to progressive disease, death (in the absence of progression), EOT (last evaluable disease assessment), whichever occurs first, approximately 18 months.

  6. PK of AZD8421 (Cmax)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; Cmax; to measure maximum plasma concentration after oral administration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  7. PK of AZD8421 (Tmax)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; Tmax; to measure time to reach maximum plasma concentration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  8. PK of AZD8421 (AUCinf)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; AUCinf; to measure the area under the plasma concentration-time curve from time 0 to infinity.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  9. PK of AZD8421 (AUClast)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; AUClast; to measure area under the plasma concentration-time curve from time zero to last PK sample.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  10. PK of AZD8421 (T1/2λZ)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; T1/2λZ; to measure the terminal elimination half-life.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  11. PK of AZD8421 (CL/F)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; CL/F; to measure apparent clearance after oral administration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  12. PK of AZD8421 (Cssmax)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; Cssmax; to measure maximum concentration after oral administration at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  13. PK of AZD8421 (Tssmax)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; Tssmax; to measure time it takes to achieve maximum plasma concentration at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  14. PK of AZD8421 (ARCmax)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; ARCmax; to measure accumulation ratio of Cmax.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  15. PK of AZD8421 (AUCsslast)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; AUCsslast; to measure the area under plasma-concentration time curve from time zero to last PK sample at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  16. PK of AZD8421 (T1/2λssz)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; T1/2λssz; to measure terminal elimination half-life at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  17. PK of AZD8421 (CLss/F)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; CLss/F; to measure apparent oral clearance at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  18. PK of AZD8421, camizestrant, and CDK4/6i (Cmax) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: Cmax; to measure maximum plasma concentration after oral administration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  19. PK of AZD8421, camizestrant, and CDK4/6i (Tmax) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: Tmax; to measure the time it takes to achieve maximum plasma concentration after oral administration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  20. PK of AZD8421, camizestrant, and CDK4/6i (AUCinf) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: AUCinf; to measure area under plasma concentration-time curve from time zero to infinity.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  21. PK of AZD8421, camizestrant, and CDK4/6i (T1/2λ) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: T1/2λZ; to measure terminal elimination half-life.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  22. PK of AZD8421, camizestrant, and CDK4/6i (CL/F) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: CL/F; to measure apparent clearance after oral administration.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  23. PK of AZD8421, camizestrant, and CDK4/6i (Cssmax) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: Cssmax; to measure the maximum plasma concentration after oral administration at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  24. PK of AZD8421, camizestrant, and CDK4/6i (Tssmax) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: Tssmax; to measure time it takes to achieve maximum plasma concentration after oral administration at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  25. PK of AZD8421, camizestrant, and CDK4/6i (AUC0-tau) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: AUC0-tau; to measure area under plasma-concentration-time curve within dosing interval.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  26. PK of AZD8421, camizestrant, and CDK4/6i (T1/2λssz) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: T1/2λssz; to measure terminal elimination half-life at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  27. PK of AZD8421, camizestrant, and CDK4/6i (CLss/F) (M2 only)

    Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: CLss/F; to measure apparent clearance after oral administration at steady state.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.

  28. PD of AZD8421 (M1B only)

    To assess pharmacodynamic activity of AZD8421 monotherapy by assessment of candidate biomarker in baseline and on-treatment tumor and blood samples in participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors.

    Time frame: Baseline and Cycle 1 Day 15.

  29. PK of AZD8421 (ARAUC)

    To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses measure accumulation ratio of AUC.

    Time frame: From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.

  30. Best Objective Response (BOR)

    The best response a participant has had following start of dosing, but prior to starting any subsequent cancer therapy and up to and including date of first documented disease progression, last evaluable assessment or death (by any cause in the absence of disease progression).

    Time frame: 8 weeks from start of treatment until end of treatment or objective disease progression, approximately 18 months.

07

Study locations

13 sites
  • Research Site
    St Louis, Missouri 63141, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Nashville, Tennessee 37201, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Pamplona, 31005, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    Cambridge, CB2 0XY, United Kingdom
  • Research Site
    London, EC1A 7BE, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 42 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Aug 2027 → Jun 2027 and completion Aug 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Jan 3, 2024
StartActual
Dec 5, 2023
Primary completionEst.
Jun 30, 2027was Aug 2027
CompletionEst.
Jun 30, 2027was Aug 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Sites
1 site removed
Show 1 removed
  • Research Site · Leeds, United Kingdom
Oct 23, 2026
Primary completion
Aug 4, 2027→Jun 30, 2027
Oct 28, 2026
Study completion
Aug 4, 2027→Jun 30, 2027
Oct 28, 2026
Enrollment
564 (estimated)→55 (actual)
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    Primary completion Aug 4, 2027→Jun 30, 2027
    Study completion Aug 4, 2027→Jun 30, 2027
  2. Oct 23, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Research Site · Leeds, United Kingdom
    Enrollment 564 (estimated)→55 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06188520
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Dec 5, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Richard Baird, MD, PhD
study chair · Cambridge University Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion